Severe asthma in children

References

1. 1.↵
   1. Chung KF,
   2. Wenzel SE,
   3. Brozek JL,
   4. Bush A,
   5. Castro M,
   6. Sterk PJ, et al.

   International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.

   OpenUrlAbstract/FREE Full Text
2. 2.
   1. Lødrup Carlsen KC,
   2. Hedlin G,
   3. Bush A,
   4. Wennergren G,
   5. de Benedictis FM,
   6. De Jongste JC, et al.

   Assessment of problematic severe asthma in children. Eur Respir J 2011; 37: 432–440.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Zeiger RS,
   2. Schatz M,
   3. Dalal AA,
   4. Qian L,
   5. Chen W,
   6. Ngor EW, et al.

   Utilization and costs of severe uncontrolled asthma in a managed-care Setting. J allergy Clin Immunol Pract 2016; 4: 120–129.

   OpenUrl
4. 4.↵
   1. Mirra V,
   2. Montella S,
   3. Santamaria F.

   Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment. BMC Pediatr 2018; 18: 73.

   OpenUrl
5. 5.↵
   1. Froidure A,
   2. Mouthuy J,
   3. Durham SR,
   4. Chanez P,
   5. Sibille Y,
   6. Pilette C.

   Asthma phenotypes and IgE responses. Eur Respir J 2016; 47: 304–319.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Fitzpatrick AM.

   Severe asthma in children: lessons learned and future directions. J Allergy Clin Immunol Pract 2016; 4: 11–19.

   OpenUrl
7. 7.↵
   1. Fleming L,
   2. Murray C,
   3. Bansal AT,
   4. Hashimoto S,
   5. Bisgaard H,
   6. Bush A, et al.

   The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J 2015; 46: 1322–1333.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. McMillan SS,
   2. King M,
   3. Tully MP.

   How to use the nominal group and Delphi techniques. Int J Clin Pharm 2016; 38: 655–662.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Haktanir Abul M,
   2. Phipatanakul W.

   Severe asthma in children: Evaluation and management. Allergol Int 2019; 68: 150–157.

   OpenUrl
10. 10.↵
    1. Ahmed H,
    2. Turner S.

    Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol 2019; 54: 778–787.
11. 11.↵
    1. Kian Fan Chung, Sally E.
    2. Wenzel, Jan L.
    3. Brozek, Andrew Bush,
    4. Mario Castro, et al.

    International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2018; 52: 1352020.

    OpenUrlFREE Full Text
12. 12.↵
    1. Lang A,
    2. Carlsen KH,
    3. Haaland G,
    4. Devulapalli CS,
    5. Munthe-Kaas M,
    6. Mowinckel P, et al.

    Severe asthma in childhood: Assessed in 10 year olds in a birth cohort study. Allergy 2008; 63: 1054–1060.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Hedlin G,
    2. Bush A,
    3. Lodrup Carlsen K,
    4. Wennergren G,
    5. De Benedictis FM,
    6. Melen E, et al.

    Problematic severe asthma in children, not one problem but many: a GA2LEN initiative. Eur Respir J 2010; 36: 196–201.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Fitzpatrick AM,
    2. Gaston BM,
    3. Erzurum SC,
    4. Teague WG

    , National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide. J Allergy Clin Immunol 2006; 118: 1218–1225.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Stern DA,
    2. Morgan WJ,
    3. Halonen M,
    4. Wright AL,
    5. Martinez FD.

    Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. Lancet 2008; 372: 1058–1064.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Håland G,
    2. Carlsen KCL,
    3. Sandvik L,
    4. Devulapalli CS,
    5. Munthe-Kaas MC,
    6. Pettersen M, et al.

    Reduced lung function at birth and the risk of asthma at 10 years of age. N Engl J Med 2006; 355: 1682–1689.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Stern DA,
    2. Morgan WJ,
    3. Wright AL,
    4. Guerra S,
    5. Martinez FD.

    Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 2007; 370: 758–764.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Smith DH,
    2. Malone DC,
    3. Lawson KA,
    4. Okamoto LJ,
    5. Battista C,
    6. Saunders WB.

    A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156: 787–793.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Martinez FD,
    2. Wright AL,
    3. Taussig LM,
    4. Holberg CJ,
    5. Halonen M,
    6. Morgan WJ.

    Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332: 133–138.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.
    1. Rasmussen F,
    2. Taylor DR,
    3. Flannery EM,
    4. Cowan JO,
    5. Greene JM,
    6. Herbison GP, et al.

    Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 2002; 165: 1480–1488.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.
    1. Covar RA,
    2. Strunk R,
    3. Zeiger RS,
    4. Wilson LA,
    5. Liu AH,
    6. Weiss S, et al.

    Predictors of remitting, periodic, and persistent childhood asthma. J Allergy Clin Immunol 2010; 125: 359–366.e6.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.
    1. Spycher BD,
    2. Silverman M,
    3. Brooke AM,
    4. Minder CE,
    5. Kuehni CE.

    Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. Eur Respir J 2008; 31: 974–981.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Alahmadi TS,
    2. Banjari MA,
    3. Alharbi AS.

    The prevalence of childhood asthma in Saudi Arabia. Int J Pediatr Adolesc Med 2019; 6: 74–77.

    OpenUrl
24. 24.↵
    1. Al-Moamary MS,
    2. Alhaider SA,
    3. Alangari AA,
    4. Idrees MM,
    5. Zeitouni MO,
    6. Al Ghobain MO, et al.

    The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med 2021; 16: 4–56.

    OpenUrl
25. 25.↵
    1. BinSaeed AA,
    2. Torchyan AA,
    3. Alsadhan AA,
    4. Almidani GM,
    5. Alsubaie AA,
    6. Aldakhail AA,

    et al. Determinants of asthma control among children in Saudi Arabia. J Asthma 2014; 51: 435–439.
26. 26.↵
    1. Foster JM,
    2. McDonald VM,
    3. Guo M,
    4. Reddel HK.

    “I have lost in every facet of my life”: the hidden burden of severe asthma. Eur Respir J 2017; 50: 1700765.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Nurmagambetov T,
    2. Kuwahara R,
    3. Garbe P.

    The economic burden of asthma in the United States, 2008-2013. Ann Am Thorac Soc 2018; 15: 348–356.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Bahadori K,
    2. Doyle-Waters MM,
    3. Marra C,
    4. Lynd L,
    5. Alasaly K,
    6. Swiston J, et al.

    Economic burden of asthma: a systematic review. BMC Pulm Med 2009; 9: 24.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Finkelstein EA,
    2. Lau E,
    3. Doble B,
    4. Ong B,
    5. Koh MS.

    Economic burden of asthma in Singapore. BMJ Open Respir Res 2021; 8: e000654.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Barnes PJ.

    Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004; 1: 264–268.

    OpenUrlCrossRefPubMed
31. 31.
    1. Wadhwa R,
    2. Dua K,
    3. Adcock IM,
    4. Horvat JC,
    5. Kim RY,
    6. Hansbro PM.

    Cellular mechanisms underlying steroid-resistant asthma. Eur Respir Rev 2019; 28: 190096.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Al-Ramli W,
    2. Préfontaine D,
    3. Chouiali F,
    4. Martin JG,
    5. Olivenstein R,
    6. Lemière C, et al.

    T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009; 123: 1185–1187.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Poon AH,
    2. Eidelman DH,
    3. Martin JG,
    4. Laprise C,
    5. Hamid Q.

    Pathogenesis of severe asthma. Clin Exp Allergy 2012; 625–637.
34. 34.↵
    1. Nagakumar P,
    2. Puttur F,
    3. Gregory LG,
    4. Denney L,
    5. Fleming L,
    6. Bush A, et al.

    Pulmonary type-2 innate lymphoid cells in paediatric severe asthma: phenotype and response to steroids. Eur Respir J 2019; 54: 1801809.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Bhavsar P,
    2. Ahmad T,
    3. Adcock IM.

    The role of histone deacetylases in asthma and allergic diseases. J Allergy Clin Immunol 2008; 121: 580–584.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.
    1. Ito K,
    2. Caramori G,
    3. Lim S,
    4. Oates T,
    5. Chung KF,
    6. Barnes PJ, et al.

    Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002; 166: 392–396.

    OpenUrlCrossRefPubMedWeb of Science
37. 37.↵
    1. Tantisira KG,
    2. Lasky-Su J,
    3. Harada M,
    4. Murphy A,
    5. Litonjua AA,
    6. Himes BE, et al.

    Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011; 365: 1173–1183.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Barnes PJ.

    Glucocorticosteroids: current and future directions. Br J Pharmacol 2011; 163: 29–43.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    1. Gagliardo R,
    2. Chanez P,
    3. Vignola AM,
    4. Bousquet J,
    5. Vachier I,
    6. Godard P, et al.

    Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. Am J Respir Crit Care Med 2000; 162: 7–13.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. Hakonarson H,
    2. Bjornsdottir US,
    3. Halapi E,
    4. Bradfield J,
    5. Zink F,
    6. Mouy M, et al.

    Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci U S A 2005; 102: 14789–14794.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Green RH,
    2. Brightling CE,
    3. Woltmann G,
    4. Parker D,
    5. Wardlaw AJ,
    6. Pavord ID.

    Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875–879.

    OpenUrlAbstract/FREE Full Text
42. 42.↵
    1. Choy DF,
    2. Hart KM,
    3. Borthwick LA,
    4. Shikotra A,
    5. Nagarkar DR,
    6. Siddiqui S, et al.

    TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 2015; 7: 301ra129.

    OpenUrlAbstract/FREE Full Text
43. 43.↵
    1. Godar M,
    2. Blanchetot C,
    3. de Haard H,
    4. Lambrecht BN,
    5. Brusselle G.

    Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs 2018; 10: 34–45.

    OpenUrl
44. 44.↵
    1. Gibson PG,
    2. Yang IA,
    3. Upham JW,
    4. Reynolds PN,
    5. Hodge S,
    6. James AL, et al.

    Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 659–668.

    OpenUrlCrossRefPubMed
45. 45.↵
    1. Pearce N,
    2. Pekkanen J,
    3. Beasley R.

    How much asthma is really attributable to atopy? Thorax 1999; 54: 268–272.

    OpenUrlFREE Full Text
46. 46.↵
    1. Yao XJ,
    2. Liu XF,
    3. Wang XD.

    Potential role of interleukin-25/interleukin-33/thymic stromal lymphopoietin-fibrocyte axis in the pathogenesis of allergic airway diseases. Chin Med J (Engl) 2018; 131: 1983–1989.

    OpenUrl
47. 47.↵
    1. Russell RJ,
    2. Brightling C.

    Pathogenesis of asthma: implications for precision medicine. Clin Sci (Lond) 2017; 131: 1723–1735.

    OpenUrl
48. 48.↵
    1. McGregor MC,
    2. Krings JG,
    3. Nair P,
    4. Castro M.

    Role of biologics in asthma. Am J Respir Crit Care Med 2019; 199: 433–445.

    OpenUrlCrossRefPubMed
49. 49.↵
    1. Pavord ID,
    2. Afzalnia S,
    3. Menzies-Gow A,
    4. Heaney LG.

    The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clin Exp Allergy 2017; 47: 148–160.

    OpenUrl
50. 50.↵
    1. Bush A,
    2. Saglani S.

    Management of severe asthma in children. Lancet 2010; 376: 814–825.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.
    1. Ramratnam SK,
    2. Bacharier LB,
    3. Guilbert TW.

    Severe asthma in children. J Allergy Clin Immunol Pract 2017; 5: 889–898.

    OpenUrl
52. 52.
    1. Montella S,
    2. Baraldi E,
    3. Cazzato S,
    4. Aralla R,
    5. Berardi M,
    6. Brunetti LM, et al.

    Severe asthma features in children: a case-control online survey. Ital J Pediatr 2016; 42: 9.

    OpenUrl
53. 53.↵
    1. Barsky EE,
    2. Giancola LM,
    3. Baxi SN,
    4. Gaffin JM.

    A practical approach to severe asthma in children. Ann Am Thorac Soc 2018; 15: 399–408.

    OpenUrl
54. 54.↵
    1. Teague WG,
    2. Phillips BR,
    3. Fahy J V,
    4. Wenzel SE,
    5. Fitzpatrick AM,
    6. Moore WC, et al.

    Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: differences with Age. J allergy Clin Immunol Pract 2018; 6: 545–554.e4.
55. 55.↵
    1. Liu AH.

    Biomarkers and childhood asthma: improving control today and tomorrow. In: Allergy & Asthma Proceedings. Rhode Island: OceanSide Publications, Inc; 2005. p. 249–254.
56. 56.↵
    1. Gaillard EA,
    2. Kuehni CE,
    3. Turner S,
    4. Goutaki M,
    5. Holden KA,
    6. de Jong CCM, et al.

    European respiratory society clinical practice guidelines for the diagnosis of asthma in children aged. Eur Respir J 2021; 58: 2004173.

    OpenUrlAbstract/FREE Full Text
57. 57.↵
    1. Lindsay JT,
    2. Heaney LG.

    Nonadherence in difficult asthma - facts, myths, and a time to act. Patient Prefer Adherence 2013; 7: 329–336.

    OpenUrlPubMed
58. 58.↵
    1. Vincken W,
    2. Levy ML,
    3. Scullion J,
    4. Usmani OS,
    5. Dekhuijzen PNR,
    6. Corrigan CJ.

    Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res 2018; 4: 00065–2018.

    OpenUrl
59. 59.↵
    1. Gautier C,
    2. Charpin D.

    Environmental triggers and avoidance in the management of asthma. J Asthma Allergy 2017; 10: 47–56.

    OpenUrlCrossRefPubMed
60. 60.↵
    1. Denlinger LC,
    2. Phillips BR,
    3. Ramratnam S,
    4. Ross K,
    5. Bhakta NR,
    6. Cardet JC, et al.

    Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med 2017; 195: 302–313.

    OpenUrl
61. 61.↵
    1. Ramphul M,
    2. Lo DKH,
    3. Gaillard EA.

    Precision medicine for paediatric severe asthma: current status and future direction. J Asthma Allergy 2021; 14: 525–538.

    OpenUrl
62. 62.↵
    1. Ridolo E,
    2. Pucciarini F,
    3. Nizi MC,
    4. Makri E,
    5. Kihlgren P,
    6. Panella L, et al.

    Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother 2020; 16: 2349–2356.

    OpenUrl
63. 63.↵
    1. Bush A.

    Which child with asthma is a candidate for biological therapies? J Clin Med 2020; 9: 1237.

    OpenUrl
64. 64.↵
    1. Fahy J V.

    Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol 2015; 15: 57–65.

    OpenUrlCrossRefPubMed
65. 65.↵
    1. Belliveau PP.

    Omalizumab: a monoclonal anti-IgE antibody. MedGenMed 2005; 7: 27.

    OpenUrlPubMed
66. 66.↵
    1. Miller CW,
    2. Krishnaswamy N,
    3. Johnston C,
    4. Krishnaswamy G.

    Severe asthma and the Omalizumab option. Clin Mol Allergy 2008; 6: 4.

    OpenUrlPubMed
67. 67.↵
    1. Hu J,
    2. Chen J,
    3. Ye L,
    4. Cai Z,
    5. Sun J,
    6. Ji K.

    Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells. Clin Transl Allergy 2018; 8: 27.

    OpenUrl
68. 68.↵
    1. Kawakami T,
    2. Blank U.

    From IgE to Omalizumab. J Immunol 2016; 197: 4187–4192.

    OpenUrlAbstract/FREE Full Text
69. 69.↵
    1. Deschildre A,
    2. Marguet C,
    3. Salleron J,
    4. Pin I,
    5. Rittié J-L,
    6. Derelle J, et al.

    Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42: 1224–1233.

    OpenUrlAbstract/FREE Full Text
70. 70.↵
    1. Thomson NC,
    2. Chaudhuri R.

    Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 2012; 6: 27–40.

    OpenUrlCrossRefPubMed
71. 71.↵
    1. Odajima H,
    2. Ebisawa M,
    3. Nagakura T,
    4. Fujisawa T,
    5. Akasawa A,
    6. Ito K, et al.

    Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol Int 2015; 64: 364–370.

    OpenUrl
72. 72.↵
    1. Brodlie M,
    2. McKean MC,
    3. Moss S,
    4. Spencer DA.

    The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 2012; 97: 604–609.

    OpenUrlAbstract/FREE Full Text
73. 73.↵
    1. Tesse R,
    2. Borrelli G,
    3. Mongelli G,
    4. Mastrorilli V,
    5. Cardinale F.

    Treating pediatric asthma according guidelines. Front Pediatr 2018; 6: 234.

    OpenUrl
74. 74.↵
    1. Gupta A,
    2. Bhat G,
    3. Pianosi P.

    What is new in the management of childhood asthma? Indian J Pediatr 2018; 85: 773–781.

    OpenUrl
75. 75.↵
    1. Lin CH,
    2. Cheng SL.

    A review of omalizumab for the management of severe asthma. Drug Des Devel Ther 2016; 10: 2369–2378.

    OpenUrl
76. 76.↵
    1. Berger W,
    2. Gupta N,
    3. McAlary M,
    4. Fowler-Taylor A.

    Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 182–188.

    OpenUrlPubMedWeb of Science
77. 77.↵
    1. Milgrom H,
    2. Fowler-Taylor A,
    3. Vidaurre CF,
    4. Jayawardene S.

    Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 2011; 27: 163–169.

    OpenUrlCrossRefPubMed
78. 78.↵
    1. Busse W,
    2. Buhl R,
    3. Fernandez Vidaurre C,
    4. Blogg M,
    5. Zhu J,
    6. Eisner MD, et al.

    Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012; 129: 983–989.e6.

    OpenUrlPubMed
79. 79.↵
    1. Rodrigo G,
    2. Neffen H.

    Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 2015; 26: 551–556.

    OpenUrl
80. 80.↵
    1. Finn A,
    2. Gross G,
    3. van Bavel J,
    4. Lee T,
    5. Windom H,
    6. Everhard F, et al.

    Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111: 278–284.

    OpenUrlCrossRefPubMedWeb of Science
81. 81.↵
    1. Votto M,
    2. De Filippo M,
    3. Licari A,
    4. Marseglia A,
    5. De Amici M,
    6. Marseglia GL.

    Biological therapies in children and adolescents with severe uncontrolled asthma: a practical review. Biologics 2021; 15: 133–142.

    OpenUrl
82. 82.↵
    1. Menzella F,
    2. Lusuardi M,
    3. Galeone C,
    4. Taddei S,
    5. Facciolongo N,
    6. Zucchi L.

    Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential. Ther Adv Chronic Dis 2016; 7: 260–277.

    OpenUrlCrossRef
83. 83.↵
    1. Emma R,
    2. Morjaria JB,
    3. Fuochi V,
    4. Polosa R,
    5. Caruso M.

    Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis 2018; 12: 1753466618808490.

    OpenUrl
84. 84.↵
    1. Liu MC,
    2. Chipps B,
    3. Munoz X,
    4. Devouassoux G,
    5. Bergna M,
    6. Smith SG, et al.

    Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respir Res 2021; 22: 144.

    OpenUrl
85. 85.↵
    1. Agache I,
    2. Song Y,
    3. Posso M,
    4. Alonso-Coello P,
    5. Rocha C,
    6. Solà I, et al.

    Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy 2021; 76: 45–58.

    OpenUrl
86. 86.↵
    1. Li Z,
    2. Radin A,
    3. Li M,
    4. Hamilton JD,
    5. Kajiwara M,
    6. Davis JD, et al.

    Pharmacokinetics, Pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects. Clin Pharmacol Drug Dev 2020; 9: 742–755.

    OpenUrl
87. 87.↵
    1. Gibson PG,
    2. Prazma CM,
    3. Chupp GL,
    4. Bradford ES,
    5. Forshag M,
    6. Mallett SA, et al.

    Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res 2021; 22: 171.

    OpenUrl
88. 88.↵
    1. Bel EH,
    2. Wenzel SE,
    3. Thompson PJ,
    4. Prazma CM,
    5. Keene ON,
    6. Yancey SW, et al.

    Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med 2014; 371: 1189–1197.

    OpenUrlCrossRefPubMedWeb of Science
89. 89.↵
    1. Khatri S,
    2. Moore W,
    3. Gibson PG,
    4. Leigh R,
    5. Bourdin A,
    6. Maspero J, et al.

    Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2019; 143: 1742–1751.e7.

    OpenUrl
90. 90.↵
    1. Sastre J,
    2. Dávila I.

    Dupilumab: A new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol 2018; 28: 139–150.

    OpenUrlCrossRef
91. 91.↵
    1. Rathinam KK,
    2. Abraham JJ,
    3. Vijayakumar TM.

    Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review. Curr Ther Res Clin Exp 2019; 91: 45–51.

    OpenUrl
92. 92.↵
    1. Brooks GD.

    Updated evaluation of dupilumab in the treatment of asthma: patient selection and reported outcomes. Ther Clin Risk Manag 2020; 16: 181–187.

    OpenUrlPubMed
93. 93.↵
    1. Numata T,
    2. Araya J,
    3. Miyagawa H,
    4. Okuda K,
    5. Fujita Y,
    6. Utsumi H, et al.

    Effectiveness of switching biologics for severe asthma patients in Japan: A single-center retrospective study. J Asthma Allergy 2021; 14: 609–618.

    OpenUrl
94. 94.↵
    1. Menzella F,
    2. Ruggiero P,
    3. Ghidoni G,
    4. Fontana M,
    5. Bagnasco D,
    6. Livrieri F, et al.

    Anti-IL5 Therapies for severe eosinophilic asthma: literature review and practical insights. J Asthma Allergy 2020; 13: 301–313.

    OpenUrl
95. 95.↵
    1. Thibodeaux Q,
    2. Smith MP,
    3. Ly K,
    4. Beck K,
    5. Liao W,
    6. Bhutani T.

    A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother 2019; 15: 2129–2139.

    OpenUrl
96. 96.↵
    1. Kim BK,
    2. Park SY,
    3. Ban GY,
    4. Kim MA,
    5. Lee JH,
    6. An J, et al.

    Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma. Allergy Asthma Immunol Res 2020; 12: 910–933.

    OpenUrl
97. 97.↵
    1. Smith M,
    2. Iqbal S,
    3. Elliott TM,
    4. Everard M,
    5. Rowe BH.

    Corticosteroids for hospitalised children with acute asthma. Cochrane database Syst Rev 2003; 2003: CD002886.
98. 98.↵
    Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. [Updated 2022]. Available from: https://ginasthma.org/
99. 99.↵
    1. Aljebab F,
    2. Choonara I,
    3. Conroy S.

    Systematic review of the toxicity of short-course oral corticosteroids in children. Arch Dis Child 2016; 101: 365–370.

    OpenUrlAbstract/FREE Full Text
100. 100.↵
     1. Aljebab F,
     2. Choonara I,
     3. Conroy S.

     Systematic review of the toxicity of long-course oral corticosteroids in children. PLoS One 2017; 12: e0170259.

     OpenUrl
101. 101.↵
     1. Gamble J,
     2. Stevenson M,
     3. McClean E,
     4. Heaney LG.

     The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180: 817–822.

     OpenUrlCrossRefPubMedWeb of Science
102. 102.↵
     1. Phipatanakul W,
     2. Mauger DT,
     3. Sorkness RL,
     4. Gaffin JM,
     5. Holguin F,
     6. Woodruff PG, et al.

     Effects of age and disease severity on systemic corticosteroid responses in asthma. Am J Respir Crit Care Med 2017; 195: 1439–1448.

     OpenUrlCrossRefPubMed
103. 103.↵
     1. Koo S,
     2. Gupta A,
     3. Fainardi V,
     4. Bossley C,
     5. Bush A,
     6. Saglani S, et al.

     Ethnic variation in response to IM triamcinolone in children with severe therapy-resistant asthma. Chest 2016; 149: 98–105.

     OpenUrl
104. 104.↵
     1. Panickar JR,
     2. Kenia P,
     3. Silverman M,
     4. Grigg J.

     Intramuscular triamcinolone for difficult asthma. Pediatr Pulmonol 2005; 39: 421–425.

     OpenUrlCrossRefPubMedWeb of Science
105. 105.↵
     1. Weil CM,
     2. Wade SL,
     3. Bauman LJ,
     4. Lynn H,
     5. Mitchell H,
     6. Lavigne J.

     The relationship between psychosocial factors and asthma morbidity in inner-city children with asthma. Pediatrics 1999; 104: 1274–1280.

     OpenUrlAbstract/FREE Full Text
106. 106.↵
     1. Alvim CG,
     2. Ricas J,
     3. Camargos PAM

     , Lasmar LMB de LF, Andrade CR de, Ibiapina C da C. “Prevalence of emotional and behavioral disorders in adolescents with asthma”. J Bras Pneumol 2008; 34: 196–204. [In Spnaish]

     OpenUrlPubMed
107. 107.↵
     1. Coban H,
     2. Aydemir Y.

     The relationship between allergy and asthma control, quality of life, and emotional status in patients with asthma: a cross-sectional study. Allergy Asthma Clin Immunol 2014; 10: 1–7.

     OpenUrlCrossRefPubMed
108. 108.↵
     1. McNichol KN,
     2. Williams HE,
     3. Allan J,
     4. McAndrew I.

     Spectrum of asthma in children—III, psychological and social components. Br Med J 1973; 4: 16–20.

     OpenUrlAbstract/FREE Full Text
109. 109.↵
     1. Banjari M,
     2. Kano Y,
     3. Almadani S,
     4. Basakran A,
     5. Al-Hindi M,
     6. Alahmadi T.

     The Relation between asthma control and quality of life in children. Int J Pediatr 2018; 2018: 6517329.

     OpenUrl
110. 110.↵
     1. Mcdonald VM,
     2. Vertigan AE,
     3. Gibson PG.

     How to set up a severe asthma service. Respirology 2011; 16: 900–911.

     OpenUrlCrossRefPubMed
111. 111.↵
     1. Lommatzsch M,
     2. Virchow JC.

     Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int 2014; 111: 847–55.

     OpenUrlCrossRefPubMed
112. 112.↵
     1. Poussel M,
     2. Thaon I,
     3. Penven E,
     4. Tiotiu AI.

     Pulmonary function testing in work-related asthma: An overview from spirometry to specific inhalation challenge. Int J Environ Res Public Health 2021; 18: 2325.

     OpenUrl
113. 113.
     1. Currie GP,
     2. Fardon TC,
     3. Lee DK.

     The role of measuring airway hyperresponsiveness and inflammatory biomarkers in asthma. Ther Clin Risk Manag 2005; 1: 83–92.

     OpenUrlCrossRefPubMed
114. 114.↵
     1. O’Byrne PM.

     Introduction: Airway hyperresponsiveness in asthma: Its measurement and clinical significance. Chest 2010; 138: 1S–3S.

     OpenUrlCrossRefPubMed
115. 115.↵
     1. Kaplan AG,
     2. Balter MS,
     3. Bell AD,
     4. Kim H,
     5. McIvor RA.

     Diagnosis of asthma in adults. CMAJ 2009; 181: E210–E220.

     OpenUrlFREE Full Text
116. 116.↵
     1. Murphy VE,
     2. Gibson PG,
     3. Talbot PI,
     4. Kessel CG,
     5. Clifton VL.

     Asthma self-management skills and the use of asthma education during pregnancy. Eur Respir J 2005; 26: 435–41.

     OpenUrlAbstract/FREE Full Text
117. 117.↵
     1. Robijn AL,
     2. Jensen ME,
     3. Gibson PG,
     4. Powell H,
     5. Giles WB,
     6. Clifton VL, et al.

     Trends in asthma self-management skills and inhaled corticosteroid use during pregnancy and postpartum from 2004 to 2017. J Asthma 2019; 56: 594–602.

     OpenUrl
118. 118.↵
     1. Hodder R,
     2. Lougheed MD,
     3. Rowe BH,
     4. FitzGerald JM,
     5. Kaplan AG,
     6. McIvor RA.

     Management of acute asthma in adults in the emergency department: Nonventilatory management. CMAJ 2010; 182: 265–272.

     OpenUrlFREE Full Text
119. 119.↵
     1. Burke H,
     2. Davis J,
     3. Evans S,
     4. Flower L,
     5. Tan A,
     6. Kurukulaaratchy R.

     A multidisciplinary team case management approach reduces the burden of frequent asthma admissions. Eur Respir J Open Res 2016; 2: 00039–02016.

     OpenUrl
120. 120.↵
     1. Narasimhan K.

     Difficult to treat and severe asthma: management strategies. Am Fam Physician 2021; 103: 286–290.

     OpenUrl
121. 121.↵
     1. Al Said A,
     2. Cushen B,
     3. Costello RW.

     Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. Ther Adv Chronic Dis 2017; 8: 31–45.

     OpenUrl
122. 122.↵
     National Asthma Education. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007; 120: S94–S138.

     OpenUrlCrossRefPubMedWeb of Science
123. 123.↵
     1. Rajan S,
     2. Gogtay N,
     3. Konwar M,
     4. Thatte U.

     The global initiative for asthma guidelines (2019): Change in the recommendation for the management of mild asthma based on the SYGMA-2 trial - A critical appraisal. Lung India 2020; 37: 169–173.